MarketResearchReports.Biz
presents this most up-to-date research on " Multiple Sclerosis -
India Drug Forecast and Market Analysis to 2024 "
Multiple
Sclerosis (MS)
is an inflammatory autoimmune disease of the central nervous system
which leads to neurological disability. The exact underlying cause of
the disease is poorly understood; however, it appears to involve a
complex combination of genetic susceptibility and a non-genetic
trigger. The MS therapeutics market has entered an exciting phase,
with an upsurge of available treatment options. Over the forecast
period, patients are expected to continue to switch to the oral
disease-modifying therapies (DMTs), lessening the stronghold of the
established injectable treatments. There are also several promising
products in the late-stage pipeline, with a diverse range of
mechanisms offering clinical advantages intended to address unmet
needs. Both pipeline and marketed DMTs are seeking approval for the
treatment of progressive MS, which currently represents a significant
unmet need. These factors are expected to increase treatment rates
throughout the 10MM resulting, driving market growth. However, this
will be largely offset by brand erosion due to the emergence of
biosimilars and generic small molecules.
India was the smallest MS
market in the 10MM in 2014, with DMT sales totaling just $19.9m.
Steady growth is anticipated to occur throughout the 10-year forecast
period, driven by the progressive launch of novel DMTs. This will
increase the diversity of available products and includes Tecfidera,
the first oral agent to launch in India. As such, treatment rates are
expected to increase considerably.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/825699
Scope
- Overview of MS including
epidemiology, etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
- Detailed information on the
key drugs in India including product MScription, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in India from 2014-2024.
- Analysis of the impact of key
events as well the drivers and restraints affecting India MS market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for MS.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2014-2024 in India.
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
Table
of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
3 Disease Overview 13
3.1 Etiology and
Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.2 Classification 15
3.2.1 Relapse-Remitting
Multiple Sclerosis 15
3.2.2 Secondary Progressive
Multiple Sclerosis 16
3.2.3 Primary Progressive
Multiple Sclerosis 16
3.2.4 Progressive Relapsing
Multiple Sclerosis 16
3.3 Symptoms 17
3.4 Prognosis 18
3.5 Quality of Life 19
4 Disease Management 20
4.1 Diagnosis 20
4.2 Treatment Overview 24
4.2.1 Management of Acute
Relapse 26
4.2.2 Treatment with
Disease-Modifying Therapies 26
4.2.3 Symptomatic Therapies 31
4.3 India 32
4.3.1 Diagnosis 32
4.3.2 Drug Treatment 32
5 Competitive Assessment 35
5.1 Overview 35
5.2 Product Profiles - Major
Injectable Brands 37
5.2.1 Betaseron 37
5.2.2 Avonex 42
5.2.3 Rebif 47
5.2.4 Copaxone 51
5.2.5 Tysabri 57
5.2.6 Lemtrada 62
5.2.7 Plegridy 69
5.3 Product Profiles - Major
Small Molecule Brands 75
5.3.1 Gilenya 75
5.3.2 Aubagio 81
5.3.3 Tecfidera 86
5.4 Other Disease-Modifying
Therapies 92
5.4.1 Overview 92
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment